388 results on '"Nalpas, B."'
Search Results
52. Pathological evolution of HCV-healthy carriers: A multivariate analysis
53. Financial Costs of Alcoholism Treatment Programs: A Longitudinal and Comparative Evaluation Among Four Specialized Centers
54. Diagnostic use of the Cobas HBV-PCR test in HBs Ag positive and HBV-DNA negative patients by standard hybridization
55. Factors participating in severe HCV-related liver disease in HIV/HCV co-infection
56. Virological and histopathological efficacy of anti-viral therapy in HCV-related cirrhosis
57. Long-term histopathological impact of IFN alpha in chronic hepatitis C
58. Long lasting suppression of disease liver activity may lead to a reversibility of cirrhosis
59. A controlled study of anti-HBV vaccine therapy in HBsAg healthy carriers
60. Marqueurs périphériques, perspectives d'avenir
61. Histological and virological evolution of long term response after ribavirin and interferon-α combination
62. Natural course of HCV infection in haemodialysed patients
63. H63D HFE gene mutation is a positive predictive factor to response to antiviral therapy in chronic hepatitis C
64. State of epidemiological knowledge and national management of hepatitis C virus infection in the European Community, 1996
65. SPECIAL ARTICLE ESBRA 1997 AWARD LECTURE: RELATIONSHIP BETWEEN EXCESSIVE ALCOHOL DRINKING AND VIRAL INFECTIONS
66. Spontaneous and iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer
67. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa
68. Hepatitis C virus genome complexity correlates with response to interferon therapy: A study in French patients with chronic hepatitis C
69. Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients
70. Serum hepatitis C virus (HCV) RNA: a reliable tool for evaluating HCV- related liver disease in anti-HCV-positive blood donors with persistently normal alanine aminotransferase values
71. Hepatocellular carcinoma in alcoholics
72. Analyse coût-avantage d'une politique de prévention vaccinale de l'hépatite virale B.
73. Assessment of red blood cell deformability in healthy adult subjects: Influence of sex, age, cigarette smoking, menstrual cycle and oral contraceptives
74. Le vin améliore-t-il la circulation ?
75. Hepatitis C virus RNA in serum of blood donors with or without elevated transaminase levels
76. Hepatitis C viremia and anti-HCV antibodies in alcoholics
77. A rational attitude toward serum alanine aminotransferase measurement by blood banks, based on a longitudinal study of a cohort of repeat blood donors
78. Dissociation of TNF and IL-1β production in chronic alcoholics without cirritosis
79. Increased erythrocyte rigidity in chronic alcoholics without cirrhosis: Deformability improvement of erythrocyte sub-populations after alcohol withdrawal
80. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease
81. Relation between HCV and HBV infections in alcoholics with or without HCC
82. Variabilité génétique du virus de l'hépatite B et son expression sérologique
83. HIV Associated infection does not preclude severity of HBV chronic liver disease
84. Significance of repeatedly normal aminotransferase activities in HCV-infected patients.
85. CLINICAL IMPACT OF DRUG ADDICTION IN ALCOHOLICS.
86. RED BLOOD CELL DEFORMABILITY AND ALCOHOL DEPENDENCE IN HUMANS.
87. EVALUATION OF mAST/tAST RATIO AS A MARKER OF ALCOHOL MISUSE IN A NON-SELECTED POPULATION.
88. An Epidemiological and Clinical Study of Transaminase Levels and Hepatitis B Antibodies in 1,100 Blood Donors.
89. Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake.
90. Monoclonal anti-HBs antibodies radioimmunoassay and serum HBV-DNA hybridization as diagnostic tools of HBV infection: relative prevalence among HBsAgnegative alcoholics, patients with chronic hepatitis or hepatocellular carcinomas and blood donors.
91. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B
92. Impact of TT virus infection in acute and chronic, viral- and non viral-related liver diseases
93. Triggering of acute alcoholic hepatitis by a-interferon therapy
94. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients
95. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users
96. A comparative study between carbohydrate-deficient transferrin and gamma-glutamyltransferase for the diagnosis of excessive drinking in a liver unit
97. SUPERSONIC SHEAR IMAGING IS A NEW POTENT MORPHOLOGICAL NON-INVASIVE TECHNIQUE TO ASSESS LIVER FIBROSIS. PART I: TECHNICAL FEASABILITY
98. A Proof of Concept, Phase II European Trial Demonstrates the Efficacy of a Novel, Extracellular Matrix-Targeted, Antioxidant in Patients With HBV- and Autoimmune Hepatitis-(AIH) Related Acute on Chronic Liver Diseases
99. EASL International Consensus Conference on Hepatitis C - Paris, 26-27 February 1999 - Consensus statement (Reprinted from Journal of Hematology, vol 30, pg 956-961, 1999)
100. A proof of concept, phase II European trial demonstrates the efficacy of a novel, extracellular matrix-targeted, antioxidant in patients with HBV- and autoimmune-(AIH) related acute on chronic liver diseases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.